Royce & Associates LP Has $9.81 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Royce & Associates LP lifted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 34.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 929,613 shares of the company’s stock after acquiring an additional 238,158 shares during the period. Royce & Associates LP’s holdings in ARS Pharmaceuticals were worth $9,807,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of ARS Pharmaceuticals by 2.9% during the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock worth $687,000 after purchasing an additional 1,824 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in ARS Pharmaceuticals by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $217,000 after buying an additional 1,962 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in ARS Pharmaceuticals by 4.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 80,641 shares of the company’s stock valued at $851,000 after buying an additional 3,433 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of ARS Pharmaceuticals by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 427,477 shares of the company’s stock valued at $4,510,000 after buying an additional 3,530 shares during the period. Finally, HighTower Advisors LLC boosted its holdings in shares of ARS Pharmaceuticals by 18.2% in the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after buying an additional 4,369 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY opened at $11.53 on Wednesday. The stock has a 50 day moving average price of $11.98 and a 200 day moving average price of $13.04. ARS Pharmaceuticals, Inc. has a 52 week low of $7.55 and a 52 week high of $18.51. The stock has a market capitalization of $1.12 billion, a PE ratio of -22.61 and a beta of 1.03.

Wall Street Analyst Weigh In

Several research firms recently commented on SPRY. Leerink Partners boosted their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Scotiabank began coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Raymond James increased their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They set an “outperform” rating and a $40.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $31.00.

Insider Activity

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00. Following the completion of the sale, the director now owns 210,346 shares of the company’s stock, valued at $2,589,359.26. This trade represents a 19.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 149,600 shares of company stock valued at $1,726,516 in the last quarter. Company insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.